Analysts’ downgrades for Friday, January 3rd:
ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by analysts at Guggenheim from a buy rating to a neutral rating. They currently have $20.00 price target on the stock, down from their previous price target of $23.00.
Bank of New York Mellon (NYSE:BK) was downgraded by analysts at Wolfe Research from an outperform rating to a peer perform rating.
Commercial Metals (NYSE:CMC) was downgraded by analysts at BNP Paribas from an outperform rating to a neutral rating.
CorVel (NASDAQ:CRVL) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.
Global Payments (NYSE:GPN) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.
Hawaiian Electric Industries (NYSE:HE) was downgraded by analysts at StockNews.com from a hold rating to a sell rating.
Imperial Oil (NYSEAMERICAN:IMO) (TSE:IMO) was downgraded by analysts at Wolfe Research from an outperform rating to a peer perform rating.
Immunovant (NASDAQ:IMVT) was downgraded by analysts at Wolfe Research from an outperform rating to a peer perform rating.
OPENLANE (NYSE:KAR) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.
Lazard (NYSE:LAZ) was downgraded by analysts at Wolfe Research from an outperform rating to a peer perform rating.
Medallion Financial (NASDAQ:MFIN) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.
Perrigo (NYSE:PRGO) was downgraded by analysts at StockNews.com from a buy rating to a hold rating.
Quisitive Technology Solutions (CVE:QUIS) was downgraded by analysts at Ventum Financial from a buy rating to a tender rating. Ventum Financial currently has C$0.57 price target on the stock, up from their previous price target of C$0.55.
Quisitive Technology Solutions (CVE:QUIS) was downgraded by analysts at Scotiabank from an outperform rating to a sector perform rating. They currently have C$0.57 price target on the stock, up from their previous price target of C$0.50.
Softchoice (TSE:SFTC) was downgraded by analysts at Scotiabank from an outperform rating to a sector perform rating. They currently have C$25.50 target price on the stock, up from their previous target price of C$24.00.
Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.